Miracle Mineral Stops Heart Disease
By Jack Taylor Posted August 29, 2021
If you or someone close to you has been diagnosed with heart disease, you already know that its a serious wake-up call. And rightfully so! Thats because heart disease can lead to deadly heart attacks making it the leading cause of DEATH here in the United States. And when it comes to treating heart disease,…
Deep Brain Stimulation And Parkinsons Disease
Remember our recent article on electroceuticals zapping different parts of the body to treat things like headaches and backaches? Well, theres been some promising research on using small electrical pulses for easing Parkinsons symptoms, a technique known as deep brain stimulation .
A Swiss startup called Aleva Neurotherapeutics has raised $57 million in disclosed funding since it was founded in 2008. Its flagship product is directSTIM, a Directional DBS System for long-term therapy in Parkinsons disease. The device must be surgically implanted in order to deliver small electric pulses into the head, which helps reduce symptoms like tremors and stiffness. Unlike similar systems, directSTIM uses an array of directional microelectrodes to focus electrical stimulation, potentially decreasing the need for exact positioning, so you dont need a surgeon with a very steady hand.
New, unrelated research published just last month provided some insight into how DBS helps Parkinsons patients. Researchers believe the treatment boosts the number and strength of mitochondria, the power plant of the cell. More juice to power the brain cells may help reduce problems like tremors. Only about 300 patients per year receive DBS treatment, according to the study.
Australian Researchers Hope Brain Gel Can Reverse Parkinsons Disease Symptoms
SYDNEY – Australian researchers say they have developed a new type of gel that could radically transform the treatment of Parkinsons disease and could also help stroke patients.
The hydrogel is made from natural amino acids, the building blocks of proteins, and has been shown to safely deliver replacement cells into damaged parts of the brain.
The gel acts as a vehicle to safely transfer stem cells into the brain. Scientists believe the process can restore damaged tissue and replace lost neurons, which affect patients with Parkinsons disease, a nervous system disorder. About 100,000 Australians are estimated to suffer from the disease, which currently has no cure.
The gel is injected as a liquid. In the brain, it reverts to a jelly-like substance and can be administered to specific areas impaired by Parkinsons or a stroke. The stem cells can then be instructed to create replacement neurons.
Nisbet said the early results are encouraging.
These all-natural hydrogels can successfully reverse the movement symptoms related to Parkinsons disease in animals, he said. But we are yet to undertake human trials, but, I mean, it is looking really promising.
Scientists say the technology could also be used to eventually treat injured knees or shoulders.
It has been published in the journal Advanced Functional Materials.
Don’t Miss: Types Of Parkinson’s Disease
Is This Popular Vitamin A Health Hazard
By Jack Taylor Posted September 4, 2021
DearTurapürTodayReader, Its no secret that taking vitamins and supplements are one of the best things you can do for your overall health. And this is especially true as you get older since vitamins help ensure your body is getting enough essential nutrients to keep it functioning properly. But its possible to have too much of…
Five Steps To Recovery Options
Five Steps to Recovery is available in three formats. Some people are visual. Other people are auditory. Still other people are both. A print book and desktop book is available for people who prefer to read the information. Recordings of the meditations are available for people who prefer to hear the information. Both formats are available for people who take in information through both their eyes and ears.
PAPERBACK: CLICK ON THE BOOK COVER BELOW TO ORDER
The 272 page paperback book contains full explanations of the five steps with transcriptions of the applicable meditations. When you order the print version of Five Steps to Recovery for $27.50 you will receive the print book in your snail mail mailbox 7-10 days after submitting your order. Click on the book cover to order your copy.
RECORDINGS
To order 4.75 hours of Five Steps to Recovery meditations click on the microphone. You will immediately receive a download link in your email and can start listening in five short minutes from now.
DESKTOP BOOK PLUS RECORDINGS .
The 272 page desktop book contains full explanations of the five steps with transcriptions of the applicable meditations. When you invest in a desktop version and meditations from Five Steps to Recovery you receive links to the download pages for both the desktop book and meditations. You can save the desktop book and meditations to your computer for review later or return to the download page whenever it is convenient to access the book and meditations.
Recommended Reading: Deep Brain Stimulation For Parkinson’s Disease Success Rate
Gene Therapy For Parkinsons Disease
Biotech companies Voyager Therapeutics and Neurocrine teamed up in January to bring an experimental gene therapy for Parkinsons disease to market. In this case, Neurocrine is investing $165 million in cash and equity into Voyager for a piece of its pipeline, including its flagship gene therapy, VY-AADC for Parkinsons. The treatment involves inserting the gene that makes AADC, an enzyme in the brain that converts levodopa into dopamine, directly into the neuron. If successful, the treatment could provide clinically meaningful improvements by restoring motor function in patients and improving symptoms following a single administration.
In fact, an earlier clinical trial showed so much promise that Voyager received a Regenerative Medicine Advanced Therapy designation for VY-AADC from the Food and Drug Administration. Only about 30 products have received an RMAT designation, which can shorten the time to market for innovative medicines. Voyager stands to make as much as $1.7 billion if all goes according to plan with VY-AADC and its other pipeline therapies, according to Xconomy.
How Is Parkinsons Disease Treated
While there is no cure for Parkinsons disease yet, doctors manage a patients symptoms to help give them a better quality of living.
Some treatments include supportive therapies, such as physiotherapy, and medication, which replace dopamine in the brain, while others require surgery.
The medications used to treat PD are the following:
-
Levodopa
-
MAO B inhibitors
-
Anticholinergics
-
Amantadine
Levodopa: This is the most common drug and is mixed with Carbidopa. This drug is digested and transformed into dopamines in the brain. Side effects of this drug include dizziness, diarrhea, loss of appetite, constipation, loss of memory, confusion, or change in the sense of taste. That is the reason why Carbidopa is added to the treatment, which deals with these side effects.
Dopamine agonists: This is an alternative to levodopa-carbidopa. It tricks the mind that it is receiving dopamine. This is less potent than levodopa and is less likely to cause dyskinesias. Side effects of dopamine agonists include nausea, hallucination, and lightheadedness. This treatment must be given at a low dose and should be increased gradually to prevent these effects.
COMT inhibitors: COMT inhibitors such as entacapone and tolcapone are some of the latest technologies in PD treatment. Although it does not directly affect the symptoms, this drug blocks the metabolism of levodopa, prolonging its effect.
RELATED: Biogen to Halt Work on Opicinumab, Steer Focus Toward Parkinsons Disease
You May Like: Movie Stars With Parkinson’s Disease
How Would A Parkinsons Vaccine Work
Parkinsons is associated with the accumulation of Lewy bodies tiny deposits of a protein called alpha-synuclein in the brain. Preventing the build-up of Lewy bodies and removing existing clumps could be an effective way to treat the disease.
Current approaches to Parkinsons vaccines involve the introduction of a molecule that induces the body to produce its own antibodies against a-syn, resulting in active immunity. It is hoped the antibodies will cling to a-syn build-ups and help to break them down.
What Research Is Being Done
The mission of the National Institute of Neurological Disorders and Stroke is to seek fundamental knowledge about the brain and nervous system and to use the knowledge to reduce the burden of neurological disease. NINDS is a component of the National Institutes of Health , the leading supporter of biomedical research in the world. NINDS conducts and supports three types of research: basicscientific discoveries in the lab, clinicaldeveloping and studying therapeutic approaches to Parkinsons disease, and translationalfocused on tools and resources that speed the development of therapeutics into practice. The goals of NINDS-supported research on Parkinsons disease are to better understand and diagnose PD, develop new treatments, and ultimately, prevent PD. NINDS also supports training for the next generation of PD researchers and clinicians and serves as an important source of information for people with PD and their families.
Also Check: Parkinson’s Phase 3 Trials
How I Reversed My Parkinsons Disease Symptoms
- SAVE
Being diagnosed with Parkinsons disease is a life-altering event. Youre presented with all these drugs to take to help ward off the unpleasant symptoms but these drugs cause unwanted side effects.
Its not a no-win situation. You can manage and possibly reverse Parkinsons disease and live a full life.
Its time to find out what you can do to help your body deal with this disease naturally and effectively. Just keep reading.
What Area Of Parkinsons Research Are You Are Excited To Find Out More About
Particularly in this COVID world that were living in, one of the things that is really exciting is were increasingly seeing the role that technology can play in helping to track the disease experience of patients.
In this unprecedented year, weve seen such a such an emphasis on sheltering in place, particularly among our vulnerable populations. We have an online clinical study called Fox Insight and weve really seen an increase in registrations because it shows the potential of being able to participate in research from the safety of your own home, and still contribute to sharing knowledge about the disease.
In the US, weve also seen the embrace of telemedicine as a way to continue to think about managing care but not necessarily having to go into a doctors office. I think all of these experiences, coupled with ongoing advances in sensor technologies or smartphone apps, really show us the way technology can ease the burden, both of managing the disease and participating in research. I think that might be a little bit of a silver lining in a world where there arent very many silver linings at the moment.
Also Check: Is There Pain With Parkinson’s
Projects In The Pipeline
A Phase I trial of Affitope PD01A, a compound developed by clinical-stage biotech AFFiRiS, demonstrated the vaccine candidates long-term safety, efficacy and tolerability. In the study, PD01A appeared to provide the longest benefit when administered as an initial shot followed by a booster.
In 2020, AFFiRiS announced it was preparing to advance PD01A into Phase II trials. This July, neurodegenerative disease-focused AC Immune acquired AFFiRiSs portfolio of therapeutics targeting alpha-synuclein, including the companys Parkinsons vaccine candidate.
AC Immune has said it will immediately launch clinical development of ACI-7104, the optimised formulation of PD01A, into an adaptive, biomarker-based Phase II study. The trial will evaluate an initial dose-response of ACI-7104, focusing on immunogenicity against a-syn and pathological a-syn species. The progression of motor and non-motor symptoms of Parkinsons disease will also be monitored, along with digital, imaging and fluid biomarkers.
Another Parkinsons vaccine candidate is UB312, a synthetic peptide-based vaccine developed by United Neuroscience, which recently merged with COVAXX to form biotech company Vaxxinity. UB312 is currently in Phase I trials to assess its safety, tolerability, and immunogenicity in healthy participants and in participants with Parkinsons disease. The study is expected to be completed in June 2022.
What Causes Parkinsons Disease
Parkinsons comes under the dementia umbrella. Its adegenerative disease of the nervous system that causes a loss of motor skillsand intentional movement. When someone has Parkinsons, the part of the brainthat controls muscular movements and mood function doesnt receive enough ofthe crucial dopamine chemical. Without enough dopamine, bodily movements,learning abilities and mood levels are severely affected. So-called normalfunctions such as speaking, writing, swallowing, walking and sleeping become difficultto perform. These challenges, combined with a lowering of mood levels is whymany Parkinsons patients suffer with depression.
You May Like: How Hereditary Is Parkinson’s Disease
New Treatment May Have The Potential To Slow Stop Or Reverse Parkinson Disease
Results from a recent study suggest that a revolutionary treatment may have the potential to slow, stop, or even reverse the progression of Parkinson disease.
Results from a February study of a revolutionary treatment suggest that it may be possible to slow, stop, or even reverse the progression of Parkinson disease, according to findings in the Journal of Parkinsons Disease.
The 3-part, experimental study investigated whether using a novel delivery system to increase levels of glial cell line-derived neurotrophic factor can regenerate dying dopamine brain cells in patients with Parkinson disease and even reverse their condition. GDNF is a naturally occurring protein that promotes the survival of many types of neurons.
I believe that this approach could be the first neuro-restorative treatment for people living with Parkinson’s, which is, of course, an extremely exciting prospect, Steven Gill, MB, MS, FRCS, who designed the infusion device used in the study, said in a statement.
Initially, 6 patients enrolled in a pilot study which evaluated the safety of the treatment approach. After the pilot study, 35 additional individuals participated in a subsequent 9-month double-blind trial. Half of the participants were randomly assigned to receive monthly infusions of GDNF while the other half received placebos.
Reference
Motivation To Write Five Steps To Recovery
I have always wanted to make a large contribution to the research world. My prior research as a scholar has certainly been well received. Other researchers cite my published articles. But in my humble opinion, the body of my research has not made a significant contribution to the world of science. What will be the difference that makes a difference for me?
Help thousands of people with the symptoms of Parkinsons feel significantly better! Five Steps to Recovery is one of the contributions I have proudly make to support this lifetime goal. Five Steps to Recovery is the foundation for anyones recovery from Parkinsons Disease.
Many people discover one therapy or another that helps reverse their symptoms by 25%, perhaps 50% or even 75%. But many call me and ask why am I not symptom free now? My response to persons who ask such questions is to suggest a transformation of thoughts that are not serving their best and highest good
You May Like: Parkinson’s Disease Brain Changes
Its Not Just One Condition There Are Multiple Types Of Parkinsons
Like cancer, we are starting to understand the importance of subtyping Parkinsons and developing tailored treatments that will be more successful than a one size fits all approach. Better understanding is coming from large scale studies that follow vast numbers of people with the condition over time. And we are starting to see how the subtypes of Parkinsons have different symptoms, progression rates and even different responses to medication.
To effectively treat Parkinsons, we probably need to tackle each of these subtypes differently, providing the right treatments and support to suit the individual and their form of Parkinsons. And this starts with understanding more about how we classify and identify these different types.
You can read more about research into personalised treatments in our recent blog Precision medicine for Parkinsons, how close are we?
Molecule Offers Hope For Halting Parkinson’s
- Date:
- Parkinson’s UK
- Summary:
- A promising molecule has offered hope for a new treatment that could stop or slow Parkinson’s, something no treatment can currently do.
A promising molecule has offered hope for a new treatment that could stop or slow Parkinson’s, something no treatment can currently do.
Researchers from the University of Helsinki found that molecule BT13 has the potential to both boost levels of dopamine, the chemical that is lost in Parkinson’s, as well as protect the dopamine-producing brain cells from dying.
The results from the study, co-funded by Parkinson’s UK and published online today in the journal Movement Disorders, showed an increase in dopamine levels in the brains of mice following the injection of the molecule. BT13 also activated a specific receptor in the mouse brains to protect the cells.
Typically, by the time people are diagnosed with Parkinson’s, they have already lost 70-80 per cent of their dopamine-producing cells, which are involved in coordinating movement.
While current treatments mask the symptoms, there is nothing that can slow down its progression or prevent more brain cells from being lost, and as dopamine levels continue to fall, symptoms get worse and new symptoms can appear.
Researchers are now working on improving the properties of BT13 to make it more effective as a potential treatment which, if successful, could benefit the 145,000 people living with Parkinson’s in the UK.
Story Source:
Recommended Reading: Early Parkinson’s Symptoms In Young Adults
Naturaltreatment For Parkinsons #6 Magnesium & Iodine:
Magnesium is vital for the health of the entire nervoussystem, especially the protective layer that surrounds the nerves . Magnesiumis also essential for the production of dopamine and helps protect dopaminergicneurons in the substantia nigra from degeneration. In addition to this, new evidence is showing that low levels of magnesium in the brain causes a build-up ofheavy metals a major factor in the development of Parkinsons, Alzheimers,epilepsy and MS. In a recent trial, 30 epileptics were given 450 mg ofmagnesium daily and this successfully controlled their seizures. Ifmagnesium can help epilepsy patients, it can certainly help Parkinsons sufferers. Worldrenowned magnesium expert and author, Dr Carolyn Dean, has both Parkinsons andAlzheimers disease in her top 55 health conditions caused by amagnesium deficiency list and says that magnesium is 100% essential for the preventionand treatment of both of these diseases Dr Carolyn Dean Interview
In regards to iodine, well-known researcher and author,Dr James Howenstein, says
Iodineis found in large quantities in the brain and the ciliary body of the eye. A lackof iodine may be involved in the production of Parkinson’s disease andglaucoma.
Inthe brain, iodine concentrates in the substantia nigra, an area of the brainthat has been associated with Parkinson’s disease.
David Brownstein M.D. 9
Best Sources of Magnesium and Iodine
-What Youll Need
1 cup of Magnesium Chloride Flakes
1 cup of Distilled Water